Yuzu extract prevents cognitive decline and impaired glucose homeostasis in β-amyloid-infused rats

Journal of Nutrition

Volumn 143, Issue 7, 2013, Pages 1093-1099

  Yang, Hye Jeong ^a   Hwang, Jin Taek ^a   Kwon, Dae Young ^a   Kim, Min Jung ^a   Kang, Suna ^b   Moon, Na Rang ^b   Park, Sunmin ^b  

^a Korea Food Research Institute   (South Korea)

^b Hoseo University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CITRUS FRUIT EXTRACT; CITRUS JUNOS TANAKA EXTRACT; DEXTRIN; FLAVONOID; INSULIN; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRUS; CITRUS JUNOS TANAKA; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; HIPPOCAMPAL CA1 REGION; IMPAIRED GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD GLUCOSE; CA1 REGION, HIPPOCAMPAL; CITRUS; COGNITION DISORDERS; DIET, HIGH-FAT; FLAVONOIDS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN; INSULIN RESISTANCE; MALE; PEPTIDE FRAGMENTS; PHENOLS; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

CITRUS JUNOS; RATTUS;

EID: 84879823974     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.112.173401     Document Type: Article

References (50)

1. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2.
2. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res. 2007;4:103-9.
3. Catindig JA, Venketasubramanian N, Ikram MK, Chen C. Epidemiology of dementia in Asia: insights on prevalence, trends and novel risk factors. J Neurol Sci. 2012;321:11-6.
4. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener. 2011;6:85.
5. Tam JH, Pasternak SH. Amyloid and Alzheimer's disease: inside and out. Can J Neurol Sci. 2012;39:286-98.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science. 2002;297: 353-6.
7. Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR, Perry G, Smith MA, Zhu X, Moreira PI. Insulin is a two-edged knife on the brain. J Alzheimers Dis. 2009;18:483-507.
8. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490:115-25.
9. Kanoski SE, Davidson TL. Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol Behav. 2011;103:59-68.
10. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev. 2010;9:399-417.
11. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10: 1049-60.
12. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280: 37377-82.
13. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 2008; 1214:177-87.
14. Onozuka H, Nakajima A, Matsuzaki K, Shin RW, Ogino K, Saigusa D, Tetsu N, Yokosuka A, Sashida Y, Mimaki Y, et al. Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008;326:739-44.
15. Singleton VL, Orthofer R, Lamuela-Ravent ́os RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Methods Enzymol. 1999;299:152-78.
16. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. J Nutr. 1993;123:1939-51.
17. Cheng YF, Wang C, Lin HB, Li YF, Huang Y, Xu JP, Zhang HT. Inhibition of phosphodiesterase-4 reverses memory deficits produced by Ab25-35 or Ab1-40 peptide in rats. Psychopharmacology (Berl). 2010; 212:181-91.
18. Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O'Donnell JM. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology. 2004;29:1432-9.
19. Park S, Kim DS, Kwon DY, Yang HJ. Long-term central infusion of adiponectin improves energy and glucose homeostasis by decreasing fat storage and suppressing hepatic gluconeogenesis without changing food intake. J Neuroendocrinol. 2011;23:687-98.
20. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M, Montminy M. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003;17:1575-80.
21. Scott Bitner R. Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics. Biochem Pharmacol. 2012; 83:705-14.
22. Kumar GP, Khanum F. Neuroprotective potential of phytochemicals. Pharmacogn Rev. 2012;6:81-90.
23. Vauzour D. Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid Med Cell Longev. 2012;2012:914273.
24. Huang SM, Tsai SY, Lin JA, Wu CH, Yen GC. Cytoprotective effects of hesperetin and hesperidin against amyloid b-induced impairment of glucose transport through downregulation of neuronal autophagy. Mol Nutr Food Res. 2012;56:601-9.
25. Williams RJ, Spencer JP. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med. 2012;52:35-45.
26. Hirota R, Roger NN, Nakamura H, Song HS, Sawamura M, Suganuma N. Anti-inflammatory effects of limonene from yuzu (Citrus junos Tanaka) essential oil on eosinophils. J Food Sci. 2010;75:H87-92.
27. Yoo KM, Lee KW, Park JB, Lee HJ, Hwang IK. Variation in major antioxidants and total antioxidant activity of yuzu (Citrus junos Sieb ex Tanaka) during maturation and between cultivars. J Agric Food Chem. 2004;52:5907-13.
28. Youdim KA, Qaiser MZ, Begley DJ. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004;36: 592-604.
29. Youdim KA, Spencer JP, Schroeter H, Rice-Evans C. Dietary flavonoids as potential neuroprotectants. Biol Chem. 2002;383:503-19.
30. Marchesi VT. Alzheimer's disease 2012: the great amyloid gamble. Am J Pathol. 2012;180:1762-7.
31. Kim DH, Kim S, Jeon SJ, Son KH, Lee S, Yoon BH, Cheong JH, Ko KH, Ryu JH. The effects of acute and repeated oroxylin A treatments on Abeta(25-35)-induced memory impairment in mice. Neuropharmacology. 2008;55:639-47.
32. Stepanichev MYu, Moiseeva YuV, Lazareva NA, Onufriev MV, Gulyaeva NV. Single intracerebroventricular administration of amyloid beta (25-35) peptide induces impairment in short-term rather than longterm memory in rats. Brain Res Bull. 2003;61:197-205.
33. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, Berezin V, Bock E. A neural cell adhesion moleculederived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience. 2007;145:209-24.
34. Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, Perault-Pochat MC, Lafay-Chebassier C. Imipramine, in part through tumor necrosis factor inhibition, prevents cognitive decline and b-amyloid accumulation in a mouse model of Alzheimers disease. J Pharmacol Exp Ther. 2010;332:505-14.
35. Zussy C, Brureau A, Delair B, Marchal S, Keller E, Ixart G, Naert G, Meunier J, Chevallier N, Maurice T, et al. Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid b fragment in rats. Am J Pathol. 2011;179:315-34.
36. Heras-Sandoval D, Ferrera P, Arias C. Amyloid-b protein modulates insulin signaling in presynaptic terminals. Neurochem Res. 2012;37: 1879-85.
37. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol. 2011;225:54-62.
38. Kosik KS. The molecular and cellular biology of tau. Brain Pathol. 1993;3:39-43.
39. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003;23:7084-92.
40. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, OrlovM, Torrance MA, Masliah E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res. 2008;86: 3265-74.
41. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimers disease: report of the NINCDSADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology. 1984;34:939-44.
42. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol. 2006;63:1312-7.
43. Berkhout AM, Cools HJ, van Houwelingen HC. The relationship between difficulties in feeding oneself and loss of weight in nursinghome patients with dementia. Age Ageing. 1998;27:637-41.
44. Akter K, Lanza EA,Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71:365-76.
45. Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev. 2011;10:264-73.
46. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord. 2006;21:175-81.
47. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimers disease. Alzheimers Dement. 2007;3:186-91.
48. Zhang Y, Zhou B, Zhang F, Wu J, Hu Y, Liu Y, Zhai Q. Amyloid-b induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway. Diabetes. 2012;61:1434-43.
49. Kumar B, Gupta SK, Srinivasan BP, Nag TC, Srivastava S, Saxena R. Hesperetin ameliorates hyperglycemia induced retinal vasculopathy via anti-angiogenic effects in experimental diabetic rats. Vascul Pharmacol. 2012;57:201-7.
50. Jung UJ, Lee MK, Jeong KS, Choi MS. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucoseregulating enzymes in C57BL/KsJ-db/db mice. J Nutr. 2004;134: 2499-503.